 | |
 | |
| Combination of | |
|---|---|
| Dimethyltryptamine | Serotonergic psychedelic; Serotonin receptor agonist |
| Harmine | Reversible inhibitor of monoamine oxidase A |
| Clinical data | |
| Other names | DMT/harmine; Harmine/dimethyltryptamine; Harmine/DMT; Dimethyltryptamine/telepathine; DMT/telepathine; Telepathine/dimethyltryptamine; telepathine/DMT; RE01 |
| Routes of administration | Unspecified1 |
Dimethyltryptamine/harmine (developmental code name RE01 or RE-01) is a combination of dimethyltryptamine (DMT), a tryptamine serotonin receptor agonist and serotonergic psychedelic, and harmine, a β-carboline reversible inhibitor of monoamine oxidase A (RIMA), which is under development for the treatment of mood disorders.123
It is a form of pharmahuasca (pharmaceutical ayahuasca), in which DMT is combined with a synthetically produced monoamine oxidase inhibitor (MAOI) as opposed to a plant-derived form such as Banisteriopsis caapi as in ayahuasca.4 Harmine, acting as a RIMA, inhibits the metabolism of DMT, in turn greatly potentiating DMT and allowing it to become orally active.567
The combination is being developed by Reconnect Labs.123 As of August 2023, it is in phase 1 clinical trials.123
See also
See also
References
References
- "Dimethyltryptamin/harmine". AdisInsight. 28 August 2023. Retrieved 28 February 2025.
- "Delving into the Latest Updates on Dimethyltryptamine/Telepathine with Synapse". Synapse. 26 January 2025. Retrieved 28 February 2025.
- "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 28 February 2025.
- Brierley DI, Davidson C (December 2012). "Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39 (2): 263–272. doi:10.1016/j.pnpbp.2012.06.001. PMID 22691716.
- Dos Santos RG, Hallak JE (November 2024). "Ayahuasca: pharmacology, safety, and therapeutic effects". CNS Spectrums. 30 (1) e2: 1–9. doi:10.1017/S109285292400213X. PMID 39564645.
- Egger K, Aicher HD, Cumming P, Scheidegger M (September 2024). "Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors". Cellular and Molecular Life Sciences. 81 (1) 395. doi:10.1007/s00018-024-05353-6. PMC 11387584. PMID 39254764.
- Berlowitz I, Egger K, Cumming P (2022). "Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca". Frontiers in Pharmacology. 13 886408. doi:10.3389/fphar.2022.886408. PMC 9121195. PMID 35600851.